CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

An eye drug biotech banks $118M and stocks its executive suite

Positive
AI Analysis

Summary

Claris Bio has secured $118M in funding and appointed Stephen Brady as CEO to lead development of a potential first-in-class therapy for limbal stem cell deficiency, a blinding condition.

Importance:5/10
Sentiment:
0.60
fundingophthalmologyleadershiprare disease
Related Companies

Read the original article

Published by BioPharma Dive on July 28, 2026 12:00 PM

Read Original